Quantitative sensory testing, commonly called QST, is a set of structured procedures that measure how your nervous system responds to carefully controlled stimuli like heat, cold, vibration, and pressure. Unlike nerve conduction studies or imaging, which look at the hardware of your nerves, QST captures the full chain from stimulus to perception, including what your brain does with the signal along the way. That makes it uniquely valuable for conditions where pain is amplified, dampened, or distorted in ways that do not show up on a scan. But it also means the results depend partly on the person being tested, which introduces complications that clinicians and researchers have spent decades trying to manage.
What Happens During a QST Session
A full QST battery typically covers both thermal and mechanical sensations. On the thermal side, a small metal plate (called a thermode) is placed against your skin. It warms or cools at a controlled rate, and you press a button or speak up when you first notice the temperature change, when it starts to feel unpleasant, and when you can no longer tolerate it. Those three moments correspond to your detection threshold, pain threshold, and pain tolerance for heat or cold. Research has confirmed that these thermal thresholds are reproducible over time, meaning that if you test the same healthy person on two separate days, you get broadly similar numbers, which is what makes longitudinal tracking possible.
On the mechanical side, clinicians use calibrated filaments, weighted probes, or pinprick devices pressed against the skin to measure how well you detect light touch, when pressure becomes painful, and how you respond to sharp stimuli. The German Research Network on Neuropathic Pain (DFNS) developed a widely adopted standardized protocol that covers nearly all aspects of somatosensation, both thermal and mechanical, and can generate a complete sensory profile for a given body region in about 30 minutes.
The standardization matters because QST is, at its core, a psychophysical test. You are reporting what you feel, not what a machine independently measures. Without tight control over stimulus delivery, instructions, and testing environment, results drift. The DFNS protocol addressed this by specifying exact equipment, ramp rates, body sites, and even the order in which tests are performed. That protocol has since been used on thousands of patients across multiple countries and has spawned dedicated reference databases for adults and children.
What QST Can Detect
The American Academy of Neurology reviewed the evidence and concluded that QST is probably or possibly useful for identifying sensory abnormalities in patients with diabetic neuropathy, small fiber neuropathies, uremic neuropathies, and demyelinating neuropathy. That language (“probably or possibly”) reflects the evidence quality at the time, mostly class II and III studies, but the clinical picture has become clearer since then.
For diabetic neuropathy in particular, QST serves as a way to catch nerve damage before it becomes clinically obvious. Tests like vibration perception threshold, pinprick detection, and heat threshold measurement have shown good specificity and positive predictive value for identifying diabetic neuropathy in both symptomatic and asymptomatic patients. That early detection window matters because intervening before significant nerve loss occurs, through tighter blood sugar control or medication changes, can slow progression.
Small fiber neuropathies are another area where QST plays a significant role, though with a caveat. When both cold and warm sensation thresholds are assessed, QST’s sensitivity for detecting small fiber problems is high. However, its specificity is considerably lower, around 46% in one head-to-head comparison with skin biopsy, which is considered the gold standard for confirming small fiber neuropathy. In practical terms, a normal QST result makes small fiber neuropathy less likely, but an abnormal result does not by itself confirm the diagnosis. Clinicians typically combine QST with skin biopsy or other tests rather than relying on it alone.
Thermal Versus Mechanical Testing and What Each Reveals
Thermal and mechanical tests are not redundant. They probe different populations of nerve fibers. Thermal detection and pain thresholds primarily assess small-diameter nerve fibers (the thinly myelinated A-delta fibers and unmyelinated C fibers), while vibration detection and light touch thresholds reflect the health of large-diameter myelinated fibers. A patient whose thermal thresholds are abnormal but whose vibration sense is intact likely has small fiber damage. The reverse pattern points to large fiber involvement.
This distinction has real diagnostic value. QST reliably evaluates small nerve fiber function through thermal and pain threshold measurements, which is useful because small fiber problems are often invisible to standard nerve conduction studies, which mainly capture large fiber activity. That gap is one of the main reasons QST was developed in the first place.
On the mechanical side, the details of stimulus delivery affect results more than you might expect. Research comparing different pinprick devices found that pain thresholds were consistently higher when stimuli were applied as a gradual ramp rather than a sudden step. Suprathreshold pain ratings were also lower with ramped stimuli. This means that a threshold measured with one device is not automatically interchangeable with a threshold measured using another, even if both claim to deliver the same force. Clinics tracking a patient over time need to use the same equipment and protocol at each visit.
Sensory Phenotyping in Neuropathic Pain
One of the more ambitious uses of QST has been to create “sensory profiles” that describe not just whether someone has a neuropathy, but what type of sensory change they are experiencing. A large DFNS study of over 1,200 patients with neuropathic pain from various causes found that 92% had at least one measurable sensory abnormality. The data revealed systematic patterns: nociceptive (pain-related) parameters tended to shift toward increased sensitivity, while non-nociceptive parameters tended to shift toward decreased sensitivity. Specific combinations of gains and losses clustered together depending on the diagnosis. Patients with central pain and polyneuropathy commonly showed mixed thermal and mechanical loss without heightened pain sensitivity, while those with peripheral nerve injuries more often had mixed loss combined with mechanical hyperalgesia.
Further analysis showed that patients with peripheral neuropathic pain can be sorted into roughly three sensory phenotypes. One group is dominated by sensory loss across modalities. A second group retains largely intact sensation but shows mild thermal hyperalgesia or touch-evoked pain. A third group has lost thermal detection but developed mechanical hyperalgesia or allodynia. These profiles cut across traditional diagnostic categories. Two patients with the same disease, say postherpetic neuralgia, might land in different phenotype groups, while two patients with completely different diseases might share a profile.
The hope driving this work is that sensory phenotypes could guide treatment choices. If a patient’s dominant problem is heightened central excitability rather than peripheral nerve loss, a centrally acting drug might be more logical than a peripheral nerve blocker. The evidence so far is suggestive but not definitive.
Dynamic QST and What It Reveals About Central Processing
Beyond static thresholds, QST can probe how your central nervous system handles pain signals using two dynamic tests: temporal summation of pain and conditioned pain modulation.
Temporal summation involves applying the same painful stimulus repeatedly at a fixed interval and asking whether the pain gets worse with each repetition. In a healthy nervous system, the perceived intensity climbs modestly before plateauing. An exaggerated wind-up response suggests that the spinal cord or brain is amplifying incoming signals, a hallmark of central sensitization. Research on temporal summation’s reliability has found that within a single testing session, it is moderately reliable, but between sessions conducted on different days, reliability drops. The highest consistency comes from measuring the absolute change in pain ratings within a single session. In clinical populations, both within-session and between-session reliability are moderate. This means temporal summation is best interpreted cautiously, ideally as part of a broader QST battery rather than as a standalone verdict.
Conditioned pain modulation, or CPM, tests the brain’s built-in “pain-inhibits-pain” system. The idea is straightforward: you apply one painful stimulus (say, immersing a hand in cold water) while simultaneously measuring the pain caused by a second stimulus at a different body site (say, pressure on the forearm). In a healthy system, the cold water pain triggers descending inhibitory signals that partially suppress the pressure pain, so it hurts less. A weak CPM response, meaning the second pain is not reduced much, suggests that the descending inhibitory system is not functioning well. This pattern has been documented across multiple chronic pain conditions. In one study, patients with hemophilia showed significantly reduced CPM responses compared to healthy controls, with a medium effect size. CPM deficits have also been identified in fibromyalgia, osteoarthritis, and chronic low back pain.
Predicting Postoperative Pain
One of the most clinically appealing applications of QST is using it before surgery to flag patients who are at elevated risk of developing significant pain afterward. The logic is that if someone already shows signs of amplified pain processing, such as exaggerated temporal summation or weak conditioned pain modulation, they may be more vulnerable to developing chronic postsurgical pain.
Reviews of the evidence suggest that temporal summation and conditioned pain modulation are the most consistently predictive QST measures for both acute and chronic postoperative pain. The predictive value appears strongest for orthopedic procedures. A systematic review focused specifically on total joint arthroplasty (hip and knee replacement) found that pressure pain threshold was associated with postsurgical pain in about half the studies that examined it, and temporal summation showed an association in about two-thirds. However, heterogeneous methods and inconsistent results across studies mean that no single QST parameter has been validated well enough to serve as a reliable clinical screening tool on its own.
In practice, preoperative QST is more of a research tool than a clinical routine at this point. But it holds genuine promise for identifying patients who might benefit from more aggressive perioperative pain management, nerve blocks, or preemptive use of medications that target central sensitization.
Fibromyalgia and Chronic Back Pain
QST has been instrumental in demonstrating that fibromyalgia involves measurable changes in pain processing, not just subjective complaints. Patients with fibromyalgia consistently show lower cold and heat pain thresholds than healthy controls, meaning they perceive pain at stimulus intensities that do not bother most people. Cluster analysis within fibromyalgia cohorts has identified distinct subgroups based on thermal pain thresholds, suggesting that the condition is not a single uniform entity.
When fibromyalgia patients are compared head-to-head with chronic back pain patients, the QST profiles look different. Fibromyalgia patients show increased thermal and mechanical pain sensitivity at the back and at a remote site (the hand), consistent with widespread central sensitization. Chronic back pain patients generally do not show that same widespread pattern; their sensitivity changes tend to be more localized. This distinction matters because it supports the idea that fibromyalgia and chronic back pain, while both involving persistent pain, operate through different underlying mechanisms and likely require different treatment strategies.
Monitoring Chemotherapy-Induced Neuropathy
Chemotherapy drugs like oxaliplatin are notorious for causing peripheral neuropathy, sometimes severely enough to force treatment changes. Researchers have investigated whether QST could detect neuropathy early enough to allow dose adjustments before serious damage sets in. The results have been mixed.
One study found that baseline vibration detection threshold before starting oxaliplatin treatment was correlated with the development of clinically significant neuropathy six months later, and that early changes in cold detection and heat pain thresholds during treatment were associated with later neuropathic pain. But the sensitivity and specificity of these threshold changes were only low to moderate. Another two-year clinical study concluded that thermal threshold impairment from oxaliplatin simply emerges too late to be useful for clinical decision-making and that standard clinician-graded toxicity scales remain the best approach for managing treatment adaptations.
QST may still prove useful in chemotherapy research settings, where tracking the full arc of nerve damage matters, but for the bedside clinician deciding whether to reduce a dose, simpler clinical grading systems currently outperform it.
The Psychological Confound
Because QST depends on self-report, psychological factors inevitably influence the numbers. This is not a fatal flaw, but it is one that clinicians and researchers must account for. A meta-analysis of studies in fibromyalgia patients found that higher levels of pain catastrophizing were associated with weaker conditioned pain modulation responses, and higher anxiety and depression were associated with lower pain thresholds. These relationships are not surprising. Anxiety heightens vigilance to threat, catastrophizing amplifies the emotional weight of a painful stimulus, and depression alters how the brain modulates incoming signals.
The practical implication is that a low pain threshold on QST does not automatically mean nerve damage or central sensitization; it could also reflect psychological distress. This is why QST results are rarely interpreted in isolation. Clinicians typically combine them with clinical examination, nerve conduction studies, imaging, and psychological screening. One research group that tracked QST consistency over a longer period found that when psychosocial factors remained stable over time, QST results also remained stable. That finding cuts both ways: it confirms that QST can be temporally reliable under the right conditions, but it also underscores that shifts in mood or coping style could produce apparent changes in sensory thresholds that have nothing to do with actual nerve function.
Testing in Children
Adapting QST for pediatric populations has required dedicated effort. Children cannot be expected to sit through the same instructions or response paradigms as adults, and their developing nervous systems mean that adult reference values do not apply. The DFNS protocol was modified for younger participants with simplified instructions and age-appropriate pain rating tools and validated in children as young as five. The results showed that children’s sensory thresholds change with age and differ between boys and girls, following developmental patterns similar to those seen in adults. Critically, the range and variance of results were similar to what is seen in adults, meaning the data are statistically well-behaved enough to interpret meaningfully.
A separate validation in Dutch children and adolescents confirmed that a standardized thermal QST protocol was feasible from about age eight onward, with only a small number of participants excluded due to attention difficulties. These pediatric reference databases are essential for any clinical application of QST in children, because comparing a ten-year-old’s threshold to an adult norm would produce misleading results.
Simplified and Portable Approaches
The full DFNS protocol, while thorough, requires specialized equipment and a trained examiner working for half an hour per body region. That is fine for a research lab or a dedicated pain center but impractical in a busy general neurology clinic or a primary care office. This has driven interest in simplified “bedside” versions of QST that use fewer, less expensive tools while preserving the most clinically important information. Research on one such simplified battery confirmed satisfactory test-retest reliability for most parameters, along with good criterion validity against the full protocol.
On the technology side, automated systems are being developed to remove examiner variability from the equation. One such platform uses wireless handheld pressure stimulators with a touchscreen interface to manage the testing process and collect patient responses. Validation showed low measurement error and the ability to distinguish chronic pain patients from healthy controls based on pressure pain thresholds. These portable, automated systems could eventually bring QST-style assessment into settings where it currently is not available, from rural clinics to postoperative recovery units. The gap between prototype validation and widespread clinical deployment remains wide, but the direction of travel is clear.
From Human Clinics to Animal Research
QST principles are not confined to human medicine. Translational pain researchers use analogous testing in animal models of osteoarthritis and other chronic pain conditions, applying controlled thermal and mechanical stimuli and measuring withdrawal responses. Recent work has compared sensory profiles in osteoarthritis-induced rat models and naturally occurring osteoarthritis in cats and dogs with human QST data. The patterns are strikingly parallel: animals with osteoarthritis show an imbalance between pain-facilitating and pain-inhibiting mechanisms similar to what is seen in human patients. Validating these overlapping profiles matters because it strengthens confidence that pain medications tested in animal models will behave similarly in human trials, and it supports the growing push toward phenotype-based treatment in veterinary medicine as well.
Can QST Guide Drug Choices
The idea that QST could match patients to the right painkiller based on their sensory profile has been floating around for over a decade. Correlations between QST parameters and analgesic responses have been observed in several contexts: heat pain threshold in experimental pain settings, pressure pain tolerance in surgical patients, and conditioned pain modulation in chronic pain. A systematic review found that temporal summation and conditioned pain modulation showed the most consistent predictive value for both chronic postoperative pain and the effectiveness of pharmacological therapies.
Yet the current evidence is not strong enough to recommend any specific QST parameter for predicting which drug will work for a given patient. The problem is not that the correlations do not exist; it is that they are modest in size, the testing methods vary enormously between studies, and no large randomized trial has yet shown that QST-guided treatment selection actually produces better outcomes than standard clinical judgment. Until that trial happens, QST-based treatment matching remains a compelling hypothesis rather than a validated clinical strategy. Researchers in the field are well aware of this gap, and several multicenter efforts are underway to standardize methods and test the phenotyping approach in prospective treatment trials.